14 Best Low Risk High Growth Stocks to Buy Now
It’s been months since the markets started to incessantly talk and hear about inflation, rate hikes, recession, layoffs and whatnot.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 1,650,000 | $155,595,000 | +4% | 2.25% |
| 2. | Citadel Investment Group Ken Griffin | 1,306,273 | $123,181,544 | +176% | 0.02% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,279,500 | $120,656,850 | +6% | 2.87% |
| 4. | Deerfield Management James E. Flynn | 1,209,714 | $114,076,030 | -31% | 2.43% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,152,189 | $108,651,423 | +189% | 1.28% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | Large Shareholder | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | Large Shareholder | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | Large Shareholder | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | Large Shareholder | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | Large Shareholder | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $115.02 | 5,000 | Director | 203,697 | 2023-09-12 | Filing | |
| $110.06 | 5,000 | Director | 203,697 | 2023-09-01 | Filing | |
| $110.93 | 824 | Officer | 17,263 | 2023-09-01 | Filing | |
| $108.22 | 1,438 | Officer | 3,460 | 2023-08-30 | Filing | |
| $106.90 | 1,295 | Officer | 4,898 | 2023-08-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,482,142 | $1,271,365,991 | 0.03% | |
| 2. | 9,570,718 | $902,518,707 | 0.02% | |
| 3. | 3,956,499 | $373,097,856 | 0.01% | |
| 4. | 2,612,800 | $246,387,040 | 3.51% | |
| 5. | 1,908,844 | $179,999,705 | 0.11% |
News See All
15 Worst Performing Healthcare Stocks in 2023
In this article, we discuss 15 worst performing healthcare stocks in 2023.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Second Quarter Results.
Neurocrine Biosciences (NBIX) Failed to Impress the Market in Q1
Harding Loevner, an asset management company, released its “Global Small Companies Equity Strategy” first-quarter 2023 investor letter. A copy of the same can be downloaded here.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Neurocrine Biosciences Reports First Quarter Results. At this time, all participants are in a listen-only mode.
5 High Growth Healthcare Stocks to Buy
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is one of the high growth healthcare companies that is working on treatments for neuropsychiatric and neurologic disorders.
Analysts Are Revising Price Targets of These 10 Stocks Post Earnings
In this article, we will discuss the 10 stocks that recently received updated price targets from analysts post earnings.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Fourth Quarter and Year End Results. At this time, all participants are in a listen-only mode.
15 Biggest Neuroscience Companies in the World
As the name suggests, neuroscience concerns itself with the development, structure, and functions of the nervous system, intending to enhance neurological health.
10 Best Healthcare Stocks For Recession
The healthcare sector in 2022 outperformed the market despite several headwinds and a negative macroeconomic backdrop.
Billionaire Hedge Funds
